Staff Members - Benha University
Potential role of calprotectin as a monitoring biomarker for clinical and sonographic activity and treatment outcome in recent-onset rheumatoid arthritis
Egyptian Rheumatology & Rehabilitation • 2016
Publication Information
Authors
Amal F. Soliman;, Basant M. Elnadya, Raneyah H. Mahmoud Shakerc,Amira I. Mansour
Keywords
calprotectin, disease activity score 28, rheumatoid arthritis, ultrasound
Journal
Egyptian Rheumatology & Rehabilitation
Publisher
Wolters Kluwer - Medknow
Volume
43
Issue
3
Pages
143-149
publication.type
International
Paper Link
Not Available
Supplementary Materials
Not Available
Abstract
Background
Calprotectin is a protein released during the activation and turnover of leukocytes. It
can be used as a biomarker of inflammatory diseases such as rheumatoid arthritis
(RA).
Aim
The current study aimed to measure the serum level of calprotectin in RA patients,
recently diagnosed and after initiation of treatment, to determine its association with
clinical disease, synovial inflammation determined by Ultrasound (US), and its
relation to therapy when compared with other inflammatory markers.
Patients and methods
A total of 32 patients with recent RA and 20 healthy individuals were assessed for
serum calprotectin level (enzyme-linked immunosorbent assay). C-reactive protein
(CRP) and erythrocyte sedimentation rate (ESR) were also measured in patients
who were reassessed 4 months after initiation of therapy. Disease activity was
evaluated by the disease activity score of 28 joints (DAS28), and US assessment
was performed.
Results
The mean level of serum calprotectin was significantly higher (P
Calprotectin is a protein released during the activation and turnover of leukocytes. It
can be used as a biomarker of inflammatory diseases such as rheumatoid arthritis
(RA).
Aim
The current study aimed to measure the serum level of calprotectin in RA patients,
recently diagnosed and after initiation of treatment, to determine its association with
clinical disease, synovial inflammation determined by Ultrasound (US), and its
relation to therapy when compared with other inflammatory markers.
Patients and methods
A total of 32 patients with recent RA and 20 healthy individuals were assessed for
serum calprotectin level (enzyme-linked immunosorbent assay). C-reactive protein
(CRP) and erythrocyte sedimentation rate (ESR) were also measured in patients
who were reassessed 4 months after initiation of therapy. Disease activity was
evaluated by the disease activity score of 28 joints (DAS28), and US assessment
was performed.
Results
The mean level of serum calprotectin was significantly higher (P